# Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access - Yahoo Finance

## Metadata
| Field | Value |
|-------|-------|
| Source | Yahoo Finance |
| URL | https://news.google.com/rss/articles/CBMidEFVX3lxTE5ZazdnWG8wNW9BR1pYdHl1X29xNlNxZldWZEZ5VlJfSlM1dlpxMks0R0hWQVF3WTdtQzY5UFhTYi0ySWdsdGR1T29GU0lwMEpVN1R1VnNraVJuUENZRU4zVWUwSExGWjhvT1Bvem5wSmxWRFd1?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-31 13:24 |
| Category | GLP-1 |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
Major pharmaceutical companies Lilly and Novo Nordisk are strategically reducing GLP-1 medication prices to expand market access, potentially accelerating obesity treatment market growth and adoption.

## Key Entities
Eli Lilly, Novo Nordisk

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
